Marker Therapeutics (MRKR) Competitors $1.25 -0.02 (-1.57%) Closing price 04/25/2025 03:51 PM EasternExtended Trading$1.27 +0.02 (+2.00%) As of 04/25/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRKR vs. RPTX, BDRX, ONCY, PEPG, IMRX, PDSB, SKYE, GANX, ICCC, and CUEShould you be buying Marker Therapeutics stock or one of its competitors? The main competitors of Marker Therapeutics include Repare Therapeutics (RPTX), Biodexa Pharmaceuticals (BDRX), Oncolytics Biotech (ONCY), PepGen (PEPG), Immuneering (IMRX), PDS Biotechnology (PDSB), Skye Bioscience (SKYE), Gain Therapeutics (GANX), ImmuCell (ICCC), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical products" industry. Marker Therapeutics vs. Repare Therapeutics Biodexa Pharmaceuticals Oncolytics Biotech PepGen Immuneering PDS Biotechnology Skye Bioscience Gain Therapeutics ImmuCell Cue Biopharma Repare Therapeutics (NASDAQ:RPTX) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment, earnings and community ranking. Do insiders & institutionals have more ownership in RPTX or MRKR? 85.1% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 21.6% of Repare Therapeutics shares are owned by company insiders. Comparatively, 14.5% of Marker Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings & valuation, RPTX or MRKR? Marker Therapeutics has lower revenue, but higher earnings than Repare Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepare Therapeutics$53.48M0.99-$93.80M-$2.00-0.63Marker Therapeutics$6.59M2.03-$8.24M-$1.20-1.04 Does the media refer more to RPTX or MRKR? In the previous week, Repare Therapeutics had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for Repare Therapeutics and 1 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 1.89 beat Repare Therapeutics' score of 1.60 indicating that Marker Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Repare Therapeutics Very Positive Marker Therapeutics Very Positive Which has more risk & volatility, RPTX or MRKR? Repare Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500. Do analysts prefer RPTX or MRKR? Repare Therapeutics presently has a consensus target price of $4.50, indicating a potential upside of 260.00%. Marker Therapeutics has a consensus target price of $13.17, indicating a potential upside of 953.33%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than Repare Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repare Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Marker Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 Does the MarketBeat Community believe in RPTX or MRKR? Marker Therapeutics received 32 more outperform votes than Repare Therapeutics when rated by MarketBeat users. Likewise, 64.66% of users gave Marker Therapeutics an outperform vote while only 64.18% of users gave Repare Therapeutics an outperform vote. CompanyUnderperformOutperformRepare TherapeuticsOutperform Votes4364.18% Underperform Votes2435.82% Marker TherapeuticsOutperform Votes7564.66% Underperform Votes4135.34% Is RPTX or MRKR more profitable? Repare Therapeutics has a net margin of -99.76% compared to Marker Therapeutics' net margin of -179.74%. Repare Therapeutics' return on equity of -40.87% beat Marker Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Repare Therapeutics-99.76% -40.87% -35.07% Marker Therapeutics -179.74%-89.63%-71.62% SummaryMarker Therapeutics beats Repare Therapeutics on 10 of the 18 factors compared between the two stocks. Get Marker Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRKR vs. The Competition Export to ExcelMetricMarker TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.39M$6.68B$5.44B$7.80BDividend YieldN/A3.17%5.43%4.30%P/E Ratio-1.047.1422.1418.40Price / Sales2.03238.89389.70101.29Price / CashN/A65.6738.2034.62Price / Book0.796.266.664.18Net Income-$8.24M$142.48M$3.21B$247.71M7 Day Performance8.70%7.90%6.16%6.56%1 Month Performance7.76%-4.23%-2.86%-2.25%1 Year Performance-71.33%-2.70%16.43%4.67% Marker Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRKRMarker Therapeutics3.9309 of 5 stars$1.25-1.6%$13.17+953.3%-71.4%$13.39M$6.59M-1.0460Short Interest ↓RPTXRepare Therapeutics3.6391 of 5 stars$1.20flat$4.50+275.0%-60.3%$51.01M$53.48M-0.60180BDRXBiodexa Pharmaceuticals0.403 of 5 stars$1.38-3.5%N/AN/A$50.43M$83,000.000.0020Short Interest ↑News CoverageGap UpONCYOncolytics Biotech1.9525 of 5 stars$0.58+2.5%$4.33+653.6%-48.5%$49.69MN/A-2.1330News CoveragePEPGPepGen2.671 of 5 stars$1.52+14.3%$10.33+579.8%-86.9%$49.69MN/A-0.5130IMRXImmuneering3.7651 of 5 stars$1.38+8.7%$12.50+805.8%+1.4%$49.52M$320,000.00-0.7060Short Interest ↓News CoveragePositive NewsPDSBPDS Biotechnology1.438 of 5 stars$1.08flat$9.00+733.3%-61.7%$49.03MN/A-0.9320Analyst RevisionNews CoverageSKYESkye Bioscience0.9475 of 5 stars$1.57+9.4%$16.60+957.3%-85.8%$48.63MN/A-2.1811News CoverageGap DownGANXGain Therapeutics2.8203 of 5 stars$1.74-3.3%$8.20+371.3%-38.3%$48.35M$50,000.00-1.5820News CoverageICCCImmuCell0.9462 of 5 stars$5.38-2.2%N/A+7.8%$48.33M$26.49M-10.7670Short Interest ↓Gap DownCUECue Biopharma4.3707 of 5 stars$0.78+2.5%$3.00+284.0%-44.3%$48.29M$9.29M-0.8760Gap Up Related Companies and Tools Related Companies Repare Therapeutics Alternatives Biodexa Pharmaceuticals Alternatives Oncolytics Biotech Alternatives PepGen Alternatives Immuneering Alternatives PDS Biotechnology Alternatives Skye Bioscience Alternatives Gain Therapeutics Alternatives ImmuCell Alternatives Cue Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRKR) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marker Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MRKR Stock Free MRKR Stock Alerts